中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2009年
24期
1662-1666
,共5页
卜丽娜%杨拴盈%杜洁%南岩东%林秀丽%郑华东%霍树芬%尚文丽%刘延峰
蔔麗娜%楊拴盈%杜潔%南巖東%林秀麗%鄭華東%霍樹芬%尚文麗%劉延峰
복려나%양전영%두길%남암동%림수려%정화동%곽수분%상문려%류연봉
肺肿瘤%癌,鳞状细胞%芯片分析技术%质谱分析法%肿瘤标记,生物学
肺腫瘤%癌,鱗狀細胞%芯片分析技術%質譜分析法%腫瘤標記,生物學
폐종류%암,린상세포%심편분석기술%질보분석법%종류표기,생물학
Lung neoplasms%Carcinoma,squamous cell%Microchip analytical procedures%Mass spectrometry%Tumor markers,biological
目的 探讨液体芯片-质谱技术(CLINPROT系统)在肺鳞癌患者血清标志蛋白筛选中的应用.方法 应用CLINPROT系统检测34例肺鳞癌患者(肺鳞癌组)、46例良性肺疾病患者(良性对照组)及44名正常人(正常对照组)的血清蛋白表达谱,应用FlexAnalysis 3.0软件进行数据分析,筛选差异表达蛋白质;采用液相色谱串联质谱(LC-MS/MS)技术鉴定标志蛋白.结果 分别比较肺鳞癌组与正常对照组以及肺鳞癌组与良性对照组血清蛋白表达谱,在质荷比(M/Z)800~10 000范围内,前者筛选出96个差异表达蛋白峰,其中M/Z为4054.13和4267.46的蛋白峰在2组间差异最大,用这2种差异蛋白建立的坐标系具有良好的区分肺鳞癌与正常人的能力;后者筛选出99个差异表达蛋白峰,其中M/Z为5065.27和4054.02的蛋白峰在2组间差异最大,用这2种差异蛋白建立的坐标系具有良好的区分肺鳞癌与良性肺疾病的能力.取M/Z为1778和1865的蛋白行LC-MS/MS鉴定,结果提示二者可能均为补体C3片段或C3前体.结论 肺鳞癌患者与正常人以及与良性肺疾病患者之间血清蛋白表达谱存在明显差异,应用液体芯片-质谱技术可能从血清中筛选出敏感性高、特异性强的肺鳞癌标志蛋白.
目的 探討液體芯片-質譜技術(CLINPROT繫統)在肺鱗癌患者血清標誌蛋白篩選中的應用.方法 應用CLINPROT繫統檢測34例肺鱗癌患者(肺鱗癌組)、46例良性肺疾病患者(良性對照組)及44名正常人(正常對照組)的血清蛋白錶達譜,應用FlexAnalysis 3.0軟件進行數據分析,篩選差異錶達蛋白質;採用液相色譜串聯質譜(LC-MS/MS)技術鑒定標誌蛋白.結果 分彆比較肺鱗癌組與正常對照組以及肺鱗癌組與良性對照組血清蛋白錶達譜,在質荷比(M/Z)800~10 000範圍內,前者篩選齣96箇差異錶達蛋白峰,其中M/Z為4054.13和4267.46的蛋白峰在2組間差異最大,用這2種差異蛋白建立的坐標繫具有良好的區分肺鱗癌與正常人的能力;後者篩選齣99箇差異錶達蛋白峰,其中M/Z為5065.27和4054.02的蛋白峰在2組間差異最大,用這2種差異蛋白建立的坐標繫具有良好的區分肺鱗癌與良性肺疾病的能力.取M/Z為1778和1865的蛋白行LC-MS/MS鑒定,結果提示二者可能均為補體C3片段或C3前體.結論 肺鱗癌患者與正常人以及與良性肺疾病患者之間血清蛋白錶達譜存在明顯差異,應用液體芯片-質譜技術可能從血清中篩選齣敏感性高、特異性彊的肺鱗癌標誌蛋白.
목적 탐토액체심편-질보기술(CLINPROT계통)재폐린암환자혈청표지단백사선중적응용.방법 응용CLINPROT계통검측34례폐린암환자(폐린암조)、46례량성폐질병환자(량성대조조)급44명정상인(정상대조조)적혈청단백표체보,응용FlexAnalysis 3.0연건진행수거분석,사선차이표체단백질;채용액상색보천련질보(LC-MS/MS)기술감정표지단백.결과 분별비교폐린암조여정상대조조이급폐린암조여량성대조조혈청단백표체보,재질하비(M/Z)800~10 000범위내,전자사선출96개차이표체단백봉,기중M/Z위4054.13화4267.46적단백봉재2조간차이최대,용저2충차이단백건립적좌표계구유량호적구분폐린암여정상인적능력;후자사선출99개차이표체단백봉,기중M/Z위5065.27화4054.02적단백봉재2조간차이최대,용저2충차이단백건립적좌표계구유량호적구분폐린암여량성폐질병적능력.취M/Z위1778화1865적단백행LC-MS/MS감정,결과제시이자가능균위보체C3편단혹C3전체.결론 폐린암환자여정상인이급여량성폐질병환자지간혈청단백표체보존재명현차이,응용액체심편-질보기술가능종혈청중사선출민감성고、특이성강적폐린암표지단백.
Objective To screen the serum biomarker proteins of lung squamous cell carcinoma (SCCs) by liquid chip-mass spectrometry technology. Methods All serum samples, including 34 SCCs, 46 benign lung diseases (BLDs) and 44 healthy individuals, were analyzed by CLINPROT system in order to study the serum protein expression profiles. Then the discriminatory proteins were detected by FlexAnalysis 3.0 software. Biomarkers were identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results Comparing the differential serum expression proteins between SCCs and healthy individuals, and SCCs and BLDs respectively. Ninty-six differential protein peaks [mass-to-charge ration (M/Z) between 800 and 10 000] were found between SCCs and healthy individuals. In these protein peaks, the expression of protein peaks at 4054. 13 M/Z and 4267.46 M/Z had the largest difference between them. The two protein peaks could accurately separate SCCs from healthy individuals by the frame of axes. Similarly, 99 differential protein peaks were automatically detected between SCCs and BLDs. In these protein peaks, the expression of protein peaks at 5065. 27 M/Z and 4054. 02 M/Z had the largest difference between them. The two protein peaks could accurately separate SCCs from BLDs by the frame of axes. Identified by LC-MS/MS, 1778 M/Z and 1865 M/Z might be assayed jointly and corresponded tocomplements C3 fragment or C3f precursor. Conclusions Differential protein expressions existed between SCCs versus healthy individuals and SCCs versus BLD patients. It is feasible to screen the diagnostic serum biomarkers of SCC with a high sensitivity and specificity by using CLINPROT system.